|
|
Vaccine Detail
|
T. cruzi DNA-prime/MVA-boost vaccine encoding TcG2 and TcG4 |
| Vaccine Information |
- Vaccine Name: T. cruzi DNA-prime/MVA-boost vaccine encoding TcG2 and TcG4
- Target Pathogen: Trypanosoma cruzi
- Target Disease: Chagas disease
- Type: Prime-boost vaccine with DNA vaccine priming
- Status: Research
- Host Species for Licensed Use: None
- Antigen: TcG2 and TcG4 (Gupta and Garg, 2012) - antigens phylogenetically conserved in clinically important T. cruzi strains, expressed in infective and intracellular stages of the parasite, and recognized by parasite-specific cellular and humoral immune responses in multiple T. cruzi-infected hosts (Bhatia et al., 2004).
- G2
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- TcG4
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
- Description: The vaccine uses a DNA-prime/MVA-boost regimen, which includes two components: (1) a DNA vaccine with pCDNA3.1 encoding T. cruzi TcG2 and TcG4, and (2) a recombinant Modified Vaccinia Ankara (MVA) viral vector expressiong the same T. cruzi TcG2 and TcG4. The DNA vaccine is used for priming vaccination, and t he MVA recombinant vaccine is used for booster vaccination (Gupta and Garg, 2012).
|
| Host Response |
|
Mouse Response
- Host Strain: C57BL/6
- Host age: 6-8 weeks old
- Host gender: Female
- Vaccination Protocol: C57BL/6 mice were injected with pCDNA3.TcG2 or pCDNA3.TcG4 (25-μg/mouse, i.m.), and corresponding rMVA (106-pfu/mouse, i.d.) at 3-weeks interval (controls: empty vector). (Gupta and Garg, 2012)
- Immune Response: Mice immunized with TcG2 and TcG4 elicited a strong parasite and antigen-specific type 1 (IgG2b>IgG1) antibody response. indicating that delivery of antigens by DNA/rMVA approach primed the immunized mice to respond with pathogen-specific effector antibodies. Indeed, challenge infection resulted in a rapid and potent expansion of antibody response in immunized mice. (Gupta and Garg, 2012)
- Challenge Protocol: Two-weeks after the last immunization, mice were challenged with T. cruzi (10,000 trypomastigotes/mouse, i.p.). (Gupta and Garg, 2012)
|
| References |
Bhatia et al., 2004: Bhatia V, Sinha M, Luxon B, Garg N. Utility of the Trypanosoma cruzi sequence database for identification of potential vaccine candidates by in silico and in vitro screening. Infection and immunity. 2004; 72(11); 6245-6254. [PubMed: 15501750].
Gupta and Garg, 2012: Gupta S, Garg NJ. Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi. Vaccine. 2012; 30(50); 7179-7186. [PubMed: 23079191].
|
|
